メインコンテンツに移動
  • 認定パートナー
  • ELGAについて
    • ELGAについて
    • 採用情報
    • イベント
  • サポート
    • ラボのプランニング
    • 製品を登録
    • Register Your Product (USA & Canada Only)
  • お問い合わせ
  • U.S.A.
  • U.K.
  • Deutschland
  • España
  • France
  • Italia
  • Brasil
  • 中国
ホーム ELGA LabWater
  • 製品
    • PURELAB
    • CENTRA
    • MEDICA
    • BIOPURE
    • ELGA全製品ライン
  • 用途
    • ガスクロマトグラフィー
    • ラボ用水の一般要件
    • 免疫組織染色
    • 分光測光法
    • 原子分光学
    • 微生物学的分析
    • 液体クロマトグラフィー
    • 細胞培養
    • 臨床生化学
    • 質量分析
    • 遺伝学
    • 電気化学
  • 純水製造技術
    • PureSure
    • ろ過
    • イオン交換
    • 活性炭
    • 紫外線
    • 逆浸透(RO)
    • 電気脱イオン処理(EDI)
  • 水中の不純物
    • 微生物&細菌
    • 有機化合物
    • 溶存ガス
    • 無機化合物
    • 粒子状物質
  • Knowledge
    • ブログ
    • ケーススタディ
    • 超純水
    • ガイド&ホワイトペーパー
  • 製品
    • PURELAB
    • CENTRA
    • MEDICA
      • Hubgrade
      • MEDICA BIOX
    • BIOPURE
    • ELGA全製品ライン
      • PURELAB® Classic
  • 用途
    • ガスクロマトグラフィー
    • ラボ用水の一般要件
    • 免疫組織染色
    • 分光測光法
    • 原子分光学
    • 微生物学的分析
    • 液体クロマトグラフィー
      • Hochleistungsflüssigkeitschromatographie (HPLC)
    • 細胞培養
    • 臨床生化学
    • 質量分析
    • 遺伝学
    • 電気化学
  • 純水製造技術
    • PureSure
    • ろ過
    • イオン交換
    • 活性炭
    • 紫外線
    • 逆浸透(RO)
    • 電気脱イオン処理(EDI)
  • 水中の不純物
    • 微生物&細菌
    • 有機化合物
    • 溶存ガス
    • 無機化合物
    • 粒子状物質
  • Knowledge
    • ブログ
      • Analytical Chemistry
      • Clinical & Pharma
      • Cool Science
      • Environment and sustainability
      • Life in the lab
      • Purelab product design
      • Science of the future
      • Water Purity
      • Water in the lab
    • ケーススタディ
      • 南アジアのAbbott Diagnostics、ELGA MEDICAシステムを選択
      • Beam Me Up, Scotty: PURELAB® Option Q Delivers Essential Ultra Pure Water
      • Argenta chooses DKSH New Zealand to deliver Ultrapure water in Animal Pharma
      • Clean Water for a Clean Future
      • LS Scientific & ELGA deliver UltraPure water to the NAFDAC Laboratory
      • Lifebrain Group chooses ELGA as water partner for new modern 24/7 PCR-COVID-19 laboratory in Vienna, Austria.
      • Critital Tests Benefit from PURELAB® Option Reliable Pure Water
      • DASA:ブラジル最大の医療診断企業
      • 免疫血清学ラボの稼働時間最大化を支援するELGA
      • Fondazione Telethon Continues to Choose ELGA Labwater as a Trusted Partner
      • ジェネリック医薬品開発における超純水(I型水+)の重要性
      • Siemens ADVIA分析装置用に市立総合病院がMEDICA®Proを導入
      • Optimale Wasserqualität für mikrobiologische Forschung und Lehre
      • PURELAB® Option R Guarantees Pure Water for Leading Microfluidics Technology
      • PURELAB® Pulse Delivers Reliable Water Quality and Quantity for a Wide Range of Applications
      • PURELAB® flex:現代的な研究手法における理想的なトレーニングシステム
      • Powering Cutting-Edge Gene Research
      • Sichere Reinstwasserversorgung für präzise Produkttests
      • Zentrale Reinstwasser-Aufbereitung für Analyser
      • ELGA LabWater and Beckman Coulter Join Forces
      • Applied New Technologies Department Improves ICP, IC & HPLC Sample Turnaround Times with PURELAB®
      • 超純水により南極の謎を解明
      • Advancing Genetic Technologies
      • Cross Infection Control: Pure and Simple
      • Researching effective new ways to prevent cardiovascular disease at the University of Columbia
    • 超純水
    • ガイド&ホワイトペーパー
      • HPLC用水の純度
      • 製薬におけるHPLC
      • 臨床でのリスクの低減
      • サステナビリティ
  • U.S.A.
  • U.K.
  • Deutschland
  • España
  • France
  • Italia
  • Brasil
  • 中国
  • プライバシーポリシー
  • 利用規約
  • 世界的な法令順守
  • 特許
  • サイト管理者情報
  • ホーム
  • New ‘designer drug’ identified in e-cigarettes
Clinical & Pharma
Cool Science

New ‘designer drug’ identified in e-cigarettes

24 10月 2022
- by Dr Alison Halliday

New 'designer drug' identified in e-cigarettes

A novel synthetic cannabinoid in seized e-cigarette liquid samples may pose a threat to the health of drug users.

Synthetic cannabinoids are a novel class of ‘designer drugs’ that first emerged in the late 2000s. A wide variety of new synthetic cannabinoids have since been identified in hundreds of different products around the world. Because of their rapid emergence, the detection and monitoring of this class of abused drugs remains a challenge, particularly as makers change their formulations frequently.

These illicit substances are often sold as ‘legal’ replacements for cannabis because they work on the same cannabinoid receptors in the brain as tetrahydrocannabinol (or THC), the main psychoactive ingredient in cannabis. However, many of the synthetic cannabinoids sold on the drug market are more potent than THC – which could help to explain why their harmful effects, such as severe and fatal poisoning, appear to be more common. People may also be exposed to large doses of these substances, which further increases the risk of their usage.

The potential for harmful effects posed by synthetic cannabinoids highlights the importance of identifying novel compounds entering the market to enable the monitoring of any adverse effects associated with their use.

In recent years, cannabinoids from the indazole-3-carboxamide family have emerged as the most frequently detected synthetic cannabinoids. So far, approximately 50 derivatives have been identified worldwide.

Forensic analyses

In a new study, published in Forensic Science International, scientists identify a novel indazole-3-carboxamide synthetic cannabinoid in seized e-cigarette liquids.1

The researchers analysed six samples seized from a suspect who was arrested for buying and selling e-cigarette liquid containing synthetic cannabinoids. They initially used gas chromatography-mass spectrometry (GC-MS) screening, isolating an unknown brominated compound. After a series of complicated analyses, they then determined the chemical structure of the novel compound using Fourier-transform infrared spectroscopy (FT-IR), high-performance liquid chromatography-high resolution quadruple-mass spectrometry (HPLC-QTOF-MS/MS) and nuclear magnetic resonance spectrometry (NMR).

The team then used quantitative NMR and GC-MS to determine the concentration of the compound in the seized e-cigarette liquid samples – which ranged between 2228-4203 mg/L.

For these experiments, the researchers used deionised water generated from an ELGA PURELAB® Chorus laboratory water purification system to minimise the risk of introducing contaminants that may affect their results.

Comprehensive characterisation

In this study, researchers identify a novel synthetic cannabinoid in the indazole-3-carboxamide family, which they newly named as ADB-BRINACA, in seized e-cigarette liquid samples.

While the potency of this novel compound is currently unknown, the considerable amount of ADB-BRINACA detected in these samples indicates that it may pose a threat to the health of drug users. It will now be important to determine the binding affinity of this synthetic cannabinoid on cannabinoid receptors and its biological activities.

The method presented in this study could be a useful technique for determining the concentration of ADB-BRINACA in test samples, in the absence of reference material.

Why choose ELGA LabWater

ELGA’s expert engineers, chemists and scientists are at the forefront of technological innovation. We continue to introduce game-changing features to the laboratory water market.



Reference:

  1. Choi, H. et al. Identification of a novel bromoindazole synthetic cannabinoid analogue in seized e-cigarette liquid: ADB-BRINACA. Forensic Sci. Int. 2022;338:111385 https://doi.org/10.1016/j.forsciint.2022.111385

 

Dr Alison Halliday
After completing an undergraduate degree in Biochemistry & Genetics at Sheffield University, Alison was awarded a PhD in Human Molecular Genetics at the University of Newcastle. She carried out five years as a Senior Postdoctoral Research Fellow at UCL, investigating the genes involved in childhood obesity syndrome. Moving into science communications, she spent ten years at Cancer Research UK engaging the public about the charity’s work. She now specialises in writing about research across the life sciences, medicine and health.








 



 

  • Enquiry
  • 見積もりを取得
  • デモを予約する
  • 承認されたパートナーを見つける

Enquiry

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

見積もりを取得

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

デモを予約する

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

ELGA LabWater US Headquarters

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
United Kingdom
電話: +44 (0) 203 567 7300
ファックス:+44 (0) 203 567 7205

ELGA LabWater本社

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
United Kingdom
電話: +44 (0) 203 567 7300
ファックス:+44 (0) 203 567 7205

ケーススタディ

  • Abbott Diagnostics(アボットダイアグノスティクス)
  • DASA Medical Diagnostics(DASA医療診断)
  • NeoDIN Medical Institute(NeoDIN医療機関)
  • UHNS(University Hospital of North Staffordshire NHS Trust/北スタンフォードシャア大学病院)
  • Olsberg Vocational College(オルスバーグ専門学校)

リソース

  • 超純水について
  • ガイド&ホワイトペーパー
  • 純水製造技術
  • 用途
  • 水中の不純物

Blogs

  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?
  • 言語
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • 他のVeoliaサイト
    • Veolia
    • Veolia Foundation
    • Veolia Water Technologies

©VWS(UK)Ltd.はELGA LabWaterとして取引されています。2023-全著作権所有。
ELGAはVeoliaのグローバルなラボ用水のブランド名です。

  • プライバシーポリシー
  • 利用規約
  • 世界的な法令順守
  • 特許
  • サイト管理者情報
Elga Veolia
TOP

© 2017 ELGA Veolia